A review on the treatment of multiple myeloma with small molecular agents in the past five years

Zhenzhen Zhang; Xin Liu; Liyun Zhao; Yaru Zhou; Jianyou Shi; Weini Chen; Jinqi Li

doi:10.1016/j.ejmech.2021.114053

A review on the treatment of multiple myeloma with small molecular agents in the past five years

Eur J Med Chem. 2022 Feb 5:229:114053. doi: 10.1016/j.ejmech.2021.114053. Epub 2021 Dec 17.

Authors

Zhenzhen Zhang¹, Xin Liu², Liyun Zhao¹, Yaru Zhou¹, Jianyou Shi³, Weini Chen⁴, Jinqi Li⁵

Affiliations

¹ Personalized Drug Therapy Key Laboratory of Sichuan Province, Department of Pharmacy, Sichuan Academy of Medical Science&Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, 610072, Chengdu, China.
² Department of Laboratory Medicine, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, 610072, Chengdu, China.
³ Personalized Drug Therapy Key Laboratory of Sichuan Province, Department of Pharmacy, Sichuan Academy of Medical Science&Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, 610072, Chengdu, China. Electronic address: [email protected].
⁴ Department of Radiology, Sichuan Provincial People's Hospital & University of Electronic Science and Technology of China Affiliated Hospital, Chengdu, 610072, China. Electronic address: [email protected].
⁵ Personalized Drug Therapy Key Laboratory of Sichuan Province, Department of Pharmacy, Sichuan Academy of Medical Science&Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, 610072, Chengdu, China. Electronic address: [email protected].

PMID: 34974338
DOI: 10.1016/j.ejmech.2021.114053

Abstract

Multiple myeloma is currently incurable, and the incidence rate is increasing year by year worldwide. Although in recent years the combined treatment plan based on proteasome inhibitors and immunomodulatory drugs has greatly improved the treatment effect of multiple myeloma, most patients still relapse and become resistant to current treatments. To solve this problem, scientists are committed to developing drugs with higher specificity, such as iberdomide, which is highly specific to ikaros and aiolos. This review aims to focus on the small molecular agents that are being researched/clinically used for the treatment of multiple myeloma, including the target mechanism, structure-activity relationship and application prospects of small molecular agents.

Keywords: Multiple myeloma; Research overview; Small molecular agents.

Publication types

Review

MeSH terms

Animals
Antineoplastic Agents / chemistry*
Antineoplastic Agents / pharmacology
Biomarkers, Tumor / chemistry
Combined Modality Therapy
Deubiquitinating Enzymes / chemistry
Drug Development
Drug Resistance
Histone Deacetylases / chemistry
Humans
Ikaros Transcription Factor / chemistry
Immunomodulating Agents / chemistry*
Immunomodulating Agents / pharmacology
Models, Molecular
Morpholines / chemistry
Morpholines / pharmacology
Multiple Myeloma / drug therapy*
Phthalimides / chemistry
Phthalimides / pharmacology
Piperidones / chemistry
Piperidones / pharmacology
Proteasome Inhibitors / chemistry*
Proteasome Inhibitors / pharmacology
Treatment Outcome
Ubiquitin-Protein Ligases / chemistry

Substances

Antineoplastic Agents
Biomarkers, Tumor
Immunomodulating Agents
Morpholines
Phthalimides
Piperidones
Proteasome Inhibitors
Ikaros Transcription Factor
iberdomide
Ubiquitin-Protein Ligases
Deubiquitinating Enzymes
Histone Deacetylases